We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MedTech Stocks' Earnings Due on Feb 23: TFX, SAUHF, BIO, PDCO
Read MoreHide Full Article
The Q4 earnings season is drawing to a close as 82.2% members of the elite S&P 500 Index have reported quarterly results so far. According to the latest Earnings Preview, the performance of the 411 index members that have already reported their financial numbers this quarter indicate that total earnings have increased 8% on 4.9% higher revenues. The beat ratio is strong with 68.9% companies surpassing bottom-line expectations and 54.7% outperforming top-line expectations.
Per the report, Medical is one of the 13 broader sectors among the 16 Zacks sectors that have so far reported earnings growth. Among the 83.3% members of this sector that have made their quarterly releases, earnings and revenue beat stand at impressive levels of 80% and 53.3%, respectively. The sector has delivered 4.8% earnings growth on the back of 5.3% higher revenues in the quarter.
What’s in Store for the Med-Product Space?
MedTech, an important part within the broader Medical sector, holds a lot of promise at this moment. We note that the republican win has ensured a great victory for the entire industry as the likely revocation of the 2.3% medical device excise tax is going to be a big bonus for both the behemoths and small players.
According to the MedTech community, the cancellation of this tax along with other taxes will directly address issues like lack of opportunity for research and development, innovation and pipeline development. It will also help in making investments needed to accelerate patient and provider access to innovative health care products. This will also help in boosting job creation and quality of patient care, offering companies in the space an opportunity to strengthen their position to cope with the new situation.
Let’s take a look at the major MedTech stocks slated to release their Oct–Dec 2016 numbers on Feb 23:
Patterson Companies, Inc. (PDCO - Free Report) : Headquartered in St. Paul, MN, Patterson Companies is one of the leading distributors of dental and animal health products. We believe a growing and diversified product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are the key catalysts for the company.
However, we cannot conclusively predict an earnings beat for Patterson as it carries a Zacks Rank #3 and has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 57 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. (Read More: Patterson Companies Q3 Earnings: What's in Store?)
This is a provider of single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It has a wide range of solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.
Teleflex is scheduled to report fourth-quarter 2016 numbers on Feb 23. We note that, in the last reported quarter, the company registered an earnings beat of 1.12% and the trailing 12-month average surprise came in at positive 6.71%. This time, it has an Earnings ESP of 0.00% with both the Most Accurate estimate and the Zacks Consensus Estimate standing at $2.08. This makes our surprise prediction difficult even though the company carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
This medical product company is a provider of a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is scheduled to report fourth-quarter 2016 numbers on Feb 23.
The company carries a Zacks Rank #5 (Strong Sell) and has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.00. We note that, in the last reported quarter, the company registered an earnings beat of 21.57% and the trailing 12-month average surprise came at negative 5.54%.
The Straumann Group is a leading player in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss.
The company is scheduled to report fourth-quarter 2016 numbers on Feb 23. The stock’s Zacks Rank #2 but its 0.00% ESP makes surprise prediction difficult. For full-year 2016, both the Most Accurate estimate and the Zacks Consensus Estimate stand at $11.82.
While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MedTech Stocks' Earnings Due on Feb 23: TFX, SAUHF, BIO, PDCO
The Q4 earnings season is drawing to a close as 82.2% members of the elite S&P 500 Index have reported quarterly results so far. According to the latest Earnings Preview, the performance of the 411 index members that have already reported their financial numbers this quarter indicate that total earnings have increased 8% on 4.9% higher revenues. The beat ratio is strong with 68.9% companies surpassing bottom-line expectations and 54.7% outperforming top-line expectations.
Per the report, Medical is one of the 13 broader sectors among the 16 Zacks sectors that have so far reported earnings growth. Among the 83.3% members of this sector that have made their quarterly releases, earnings and revenue beat stand at impressive levels of 80% and 53.3%, respectively. The sector has delivered 4.8% earnings growth on the back of 5.3% higher revenues in the quarter.
What’s in Store for the Med-Product Space?
MedTech, an important part within the broader Medical sector, holds a lot of promise at this moment. We note that the republican win has ensured a great victory for the entire industry as the likely revocation of the 2.3% medical device excise tax is going to be a big bonus for both the behemoths and small players.
According to the MedTech community, the cancellation of this tax along with other taxes will directly address issues like lack of opportunity for research and development, innovation and pipeline development. It will also help in making investments needed to accelerate patient and provider access to innovative health care products. This will also help in boosting job creation and quality of patient care, offering companies in the space an opportunity to strengthen their position to cope with the new situation.
Let’s take a look at the major MedTech stocks slated to release their Oct–Dec 2016 numbers on Feb 23:
Patterson Companies, Inc. (PDCO - Free Report) : Headquartered in St. Paul, MN, Patterson Companies is one of the leading distributors of dental and animal health products. We believe a growing and diversified product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are the key catalysts for the company.
However, we cannot conclusively predict an earnings beat for Patterson as it carries a Zacks Rank #3 and has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 57 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. (Read More: Patterson Companies Q3 Earnings: What's in Store?)
Patterson Companies, Inc. Price and EPS Surprise
Patterson Companies, Inc. Price and EPS Surprise | Patterson Companies, Inc. Quote
Teleflex Incorporated (TFX - Free Report)
This is a provider of single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It has a wide range of solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.
Teleflex is scheduled to report fourth-quarter 2016 numbers on Feb 23. We note that, in the last reported quarter, the company registered an earnings beat of 1.12% and the trailing 12-month average surprise came in at positive 6.71%. This time, it has an Earnings ESP of 0.00% with both the Most Accurate estimate and the Zacks Consensus Estimate standing at $2.08. This makes our surprise prediction difficult even though the company carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Teleflex Incorporated Price and EPS Surprise
Teleflex Incorporated Price and EPS Surprise | Teleflex Incorporated Quote
Laboratories, Inc. (BIO - Free Report)
This medical product company is a provider of a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is scheduled to report fourth-quarter 2016 numbers on Feb 23.
The company carries a Zacks Rank #5 (Strong Sell) and has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at $1.00. We note that, in the last reported quarter, the company registered an earnings beat of 21.57% and the trailing 12-month average surprise came at negative 5.54%.
Bio-Rad Laboratories, Inc. Price and EPS Surprise
Bio-Rad Laboratories, Inc. Price and EPS Surprise | Bio-Rad Laboratories, Inc. Quote
Straumann Holding AG
The Straumann Group is a leading player in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss.
The company is scheduled to report fourth-quarter 2016 numbers on Feb 23. The stock’s Zacks Rank #2 but its 0.00% ESP makes surprise prediction difficult. For full-year 2016, both the Most Accurate estimate and the Zacks Consensus Estimate stand at $11.82.
Straumann Holding AG Price and EPS Surprise
Straumann Holding AG Price and EPS Surprise | Straumann Holding AG Quote
Now See Our Private Investment Ideas
While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>